Earlier this week, drugmaker Sanofi (NYSE: SNY ) won approval for its multiple sclerosis treatment Lemtrada in the European Union. While the drug has yet to get the green light in the U.S., it is a key addition to Sanofi's multiple sclerosis lineup, which also includes the oral medication Aubagio. But can the company compete with Biogen (NASDAQ: BIIB ) and its recently launched MS medication Tecfidera? Analysts David Williamson and Max Macaluso discuss this market in the following video.
9 rock-solid dividend stocks
One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
Editor's note: At 6:36, the speaker incorrectly states that Sanofi had a partnership with Rigel Pharmaceuticals. The Fool regrets the error.